A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Clinical trial NCT01204710 · COMPLETED

Trial details

NCT number: NCT01204710
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Prostate Cancer

Start date: 2010-10-01
Primary completion: 2012-09-01
Enrollment: 123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.